Krystal Biotech, Inc. Share Price
KRYSKrystal Biotech, Inc. Stock Performance
Open $276.01 | Prev. Close $285.05 | Circuit Range N/A |
Day Range $273.94 - $281.50 | Year Range $122.80 - $295.98 | Volume 11,828 |
Average Traded $277.31 |
Krystal Biotech, Inc. Share Price Chart
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
16-Jan-26 | $282.31 | $284.90 | +0.94% |
15-Jan-26 | $289.60 | $282.26 | -3.32% |
14-Jan-26 | $292.15 | $291.95 | -0.06% |
13-Jan-26 | $272.40 | $292.13 | +7.16% |
12-Jan-26 | $257.34 | $272.62 | +4.36% |
09-Jan-26 | $254.00 | $261.23 | +4.92% |
08-Jan-26 | $246.00 | $248.99 | +1.09% |